Fig. 3.

Precision and Systems Medicine Paradigm in Cardio-Oncology. A Precision or Systems Medicine nomogram, fingerprint, or signature consisting of genomic, transcriptomic, microRNA regulomics, epigenomic, proteomic, metabolomic, and other ‘omic’ factors could be determined for each patient, with assessment of their genetic/genomic variants that may associated with cardiotoxicity, potentially utilizing network medicine and computational pathway analyses in integrative algorithms. The output of such algorithms would be prediction of whether a patient with cancer, based on their unique characteristics, might be at low or high risk for developing cardiotoxicity, and whether they may be more or less likely to respond to specific cancer therapies. Adapted from [29], with permission.